Skip to main navigation Skip to search Skip to main content

Erratum: Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo (Science Translational Medicine DOI: 10.1126/scitranslmed.aat6420)

  • J. L. Garrido
  • , J. Presscott
  • , M. Calvo
  • , F. Bravo
  • , R. Alvarez
  • , A. Salas
  • , R. Riquelme
  • , M. L. Rioseco
  • , B. N. Williamson
  • , E. Haddock
  • , H. Feldmann
  • , M. I. Barria

Research output: Contribution to journalComment/debate

Abstract

In the Discussion of the Research Article “Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo,” one sentence was updated from “In contrast, human recombinant Abs isolated from subjects who have survived infection have the advantages to be somatically hypermutated, whereas Abs derived from immunization do not have (43)” to “In contrast, human recombinant Abs isolated from subjects who have survived infection have the advantage of being effective and naturally optimized (43).” The PDF and HTML (full text) have been corrected.

Original languageEnglish
Article numbereaaw4903
JournalScience Translational Medicine
Volume11
Issue number475
DOIs
StatePublished - 2019

Bibliographical note

Publisher Copyright:
Copyright © 2019, American Association for the Advancement of Science.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Erratum: Two recombinant human monoclonal antibodies that protect against lethal Andes hantavirus infection in vivo (Science Translational Medicine DOI: 10.1126/scitranslmed.aat6420)'. Together they form a unique fingerprint.

Cite this